Quick Takeaways
- Erick Lucera has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,529,793.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Erick Lucera
- Location
- North Andover, MA
- Summary
- The estimated net worth of Erick Lucera is at least $2,529,793 dollars as of 03 Apr 2026. Erick Lucera is the Chief Financial Officer of Dyne Therapeutics, Inc. and owns shares of Dyne Therapeutics, Inc. (DYN) stock worth about $2.34M. Erick Lucera is the EVP, CHIEF FINANCIAL OFFICER of Editas Medicine, Inc. and owns shares of Editas Medicine, Inc. (EDIT) stock worth about $192.8K.
- Signature
- /s/ Ron Caponigro, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Erick Lucera and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Dyne Therapeutics, Inc. ($2,336,952).
- Past-year value change for that position: -$106,751.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Erick Lucera
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | Chief Financial Officer | $2,336,952 | -$106,751 | -4.4% | 01 Apr 2026 |
| EDIT | Editas Medicine, Inc. | Evp, Chief Financial Officer | $192,841 | 08 Mar 2025 | ||
| AVEO | AVEO PHARMACEUTICALS, INC. | Chief Financial Officer | 19 Jan 2023 | |||
| XAIR | Beyond Air, Inc. | Director | 04 Nov 2025 | |||
| BBLG, BBLGW | Bone Biologics Corp | Director | 18 Sep 2023 | |||
| SABS, SABSW | SAB Biotherapeutics, Inc. | Director | 16 Dec 2025 |
Insider Transactions Reported by Erick Lucera:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.